Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
Harpoon Therapeutics Inc
NASDAQ HARP
Data sourced from
and
and
Harpoon Therapeutics Inc Total Liabilities to Total Assets Ratio 3 year CAGR for the quarter ending September 30, 2023: 10.60%
Harpoon Therapeutics Inc Total Liabilities to Total Assets Ratio 3 year CAGR is 10.60% for the quarter ending September 30, 2023, a -77.84% change year over year. The total liabilities to total assets ratio measures the proportion of total liabilities to total assets. It is calculated by dividing the total liabilities by the total assets. This ratio provides insights into the company's financial leverage and the proportion of its assets financed by liabilities. A higher ratio indicates a higher level of financial risk and reliance on liabilities for asset acquisition. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
-
Harpoon Therapeutics Inc Total Liabilities to Total Assets Ratio for the quarter ending September 30, 2022 was 0.80, a 42.57% change year over year.
-
Harpoon Therapeutics Inc Total Liabilities to Total Assets Ratio for the quarter ending September 30, 2021 was 0.56, a -16.35% change year over year.
-
Harpoon Therapeutics Inc Total Liabilities to Total Assets Ratio for the quarter ending September 30, 2020 was 0.67, a 170.81% change year over year.
-
Harpoon Therapeutics Inc Total Liabilities to Total Assets Ratio for the quarter ending September 30, 2019 was 0.25, a -89.54% change year over year.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: HARP
| CEO | Ms. Julie M. Eastland M.B.A. |
| IPO Date | Feb. 8, 2019 |
| Location | United States |
| Headquarters | 131 Oyster Point Boulevard, South San Francisco, CA, United States, 94080 |
| Employees | 53 |
| Sector | Healthcare |
| Industry | Biotechnology |
Description
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. It has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. The company was incorporated in 2015 and is headquartered in South San Francisco, California. As of March 11, 2024, Harpoon Therapeutics, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC.
Key trends
Similar companies
Stoke Therapeutics Inc
NA
NA
StockViz Staff
September 19, 2024
Any question? Send us an email